Zentalis Pharmaceuticals, Inc. (ZNTL)
- Previous Close
11.77 - Open
11.18 - Bid 10.94 x 200
- Ask 11.05 x 100
- Day's Range
10.39 - 11.28 - 52 Week Range
9.56 - 31.46 - Volume
1,077,395 - Avg. Volume
835,250 - Market Cap (intraday)
779.498M - Beta (5Y Monthly) 1.73
- PE Ratio (TTM)
-- - EPS (TTM)
-4.47 - Earnings Date May 8, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
34.40
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
zentalis.comRecent News: ZNTL
Performance Overview: ZNTL
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZNTL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZNTL
Valuation Measures
Market Cap
779.50M
Enterprise Value
339.73M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.78
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-1.35
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-28.53%
Return on Equity (ttm)
-67.09%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-292.19M
Diluted EPS (ttm)
-4.47
Balance Sheet and Cash Flow
Total Cash (mrq)
482.92M
Total Debt/Equity (mrq)
10.46%
Levered Free Cash Flow (ttm)
-86.97M